Compare Biogen Inc (BIIB) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Remitly Global Inc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Remitly Global Inc trades at $23.77 (market cap $4.97B). The key difference: Biogen Inc is far larger — about 6.1× Remitly Global Inc's market cap. Which is the better fit depends on your goals.
| BIIB | RELY | |
|---|---|---|
Market Cap | $30.13B | $4.97B |
Sector | Health | Technology |
52-Week High | $216.63 | $25.93 |
52-Week Low | $128.93 | $12.20 |
Enterprise Value | $37.20B | $4.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
